Leukemia

Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Patients with treatment-naïve chronic lymphocytic leukemia with the presence of deletion 17p who received treatment with ibrutinib in the first line were more likely to have poor survival and to discontinue treatment due to progression vs those without.

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

Based on results from an ongoing phase 1/2 trial, the FDA has granted fast track designation to HM432939 for patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.

High rates of hematopoietic cell transplantation were observed in patients with relapsed/refractory acute myeloid leukemia who received 131-iodine conditioning in the phase 3 SIERRA trial.

Patients with previously untreated IDH1-mutant acute myeloid leukemia experienced significant clinical benefit following treatment with ivosidenib and azacitidine compared with the placebo combination.

TG Therapeutics made the decision to voluntarily pull the biologics license application and supplemental new drug application for ublituximab/umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

In an interview with CancerNetwork®, Paul Barr, MD, discusses 8-year follow-up data from the phase 3 RESONATE-2 trial, assessing first-line ibrutinib in patients 65 years of age or older with chronic lymphocytic leukemia.

The FDA has lifted its partial clinical hold on magrolimab and azacitidine studies for patients with acute myeloid leukemia and myelodysplastic syndrome.

Investigators uncovered potential mechanisms of resistance to CD19-directed CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia.

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

Longer and more durable remissions were identified with the addition of CART-19 to ibrutinib for patients with chronic lymphocytic leukemia.

In an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.

The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.

Based on results from a phase 1 trial, the FDA has granted fast track designation to PRGN-3006 UltraCAR-Tin relapsed/refractory acute myeloid leukemia.

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Pediatric patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma experienced an improvement in survival following treatment with bortezomib and chemotherapy.

A supplemental new drug application for ivosidenib plus azacitidine was granted priority review by the FDA for previously untreated patients with IDH1-mutant acute myeloid leukemia.

Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment with a hypomethylating agent plus venetoclax followed by hematopoietic stem cell transplant could improve outcomes in patients with treated secondary acute myeloid leukemia.

New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.

The FDA has granted IO-202, a LILRB4 checkpoint inhibitor, fast track designation for the treatment of relapsed or refractory acute myeloid leukemia.

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19, according to a prospective study.

Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.